Literature DB >> 7539190

The Agency for Health Care Policy and Research. Clinical guidelines for the diagnosis and treatment of benign prostatic hyperplasia.

C G Roehrborn1.   

Abstract

The BPH guidelines provide a rational diagnostic and treatment algorithm for practitioners consulting with patients presenting with symptoms of prostatism. The guidelines also serve several very important purposes: They represent the first attempt at a comprehensive review of the English-language literature regarding the evaluation and treatment of men presenting with symptoms of BPH. They are presented in a comprehensible and transparent fashion to the reader, inasmuch as each piece of supporting evidence is explicitly listed. A decision diagram is presented, allowing health care providers to evaluate and treat patients with BPH in a rational fashion. A balance sheet of treatment outcomes should help patients and health care providers in their shared decision-making regarding treatment alternatives. They uncovered significant knowledge gaps and areas for future basic and clinical research. As more and more treatment alternatives become available, the guidelines will have to be updated to reflect both the changing health care environment and the ever-expanding armamentarium of treatment choices.

Entities:  

Mesh:

Year:  1995        PMID: 7539190

Source DB:  PubMed          Journal:  Urol Clin North Am        ISSN: 0094-0143            Impact factor:   2.241


  6 in total

Review 1.  Tamsulosin: an update of its role in the management of lower urinary tract symptoms.

Authors:  Katherine A Lyseng-Williamson; Blair Jarvis; Antona J Wagstaff
Journal:  Drugs       Date:  2002       Impact factor: 9.546

2.  A Comparison of Varying alpha-Blockers and Other Pharmacotherapy Options for Lower Urinary Tract Symptoms.

Authors:  Christopher R Chapple
Journal:  Rev Urol       Date:  2005

Review 3.  Tamsulosin: a review of its pharmacology and therapeutic efficacy in the management of lower urinary tract symptoms.

Authors:  Christopher J Dunn; Anna Matheson; Diana M Faulds
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923

Review 4.  Measurement of benign prostatic hyperplasia treatment effects on male sexual function.

Authors:  T A Skolarus; J T Wei
Journal:  Int J Impot Res       Date:  2009-06-18       Impact factor: 2.896

5.  Practice patterns regarding prostate cancer and benign prostatic hyperplasia in Japanese primary care practitioners.

Authors:  Takashi Fukagai; Kunitaka Maruyama; Masakazu Nagata; Masashi Morita; Michio Naoe; Hideki Yoshida
Journal:  Int J Urol       Date:  2007-05       Impact factor: 3.369

6.  Patterns in the diagnosis and management of benign prostatic hyperplasia in a country that does not have country-specific clinical practice guidelines.

Authors:  Jae-Seung Paick; Soo Woong Kim; Ja Hyeon Ku
Journal:  Yonsei Med J       Date:  2007-04-30       Impact factor: 2.759

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.